Catalog No.
Product Name
Application
Product Information
Citations
-
PSMA Ligand
PSMA Ligand 3 is a ligand specifically targeting Prostate-Specific Membrane Antigen (PSMA). Its primary function is to bind to PSMA, facilitating the detection and imaging of prostate cancer cells. This compound is valuable in cancer research, particularly in the study of prostate cancer diagnostics and therapy. -
PSMA Binder
PSMA binder-3 is a selective binder for Prostate-Specific Membrane Antigen (PSMA), a key target in prostate cancer research. This high-affinity ligand exhibits strong binding capabilities that facilitate the study of PSMA's role in tumor biology and therapeutic targeting. It is an essential tool for applications in imaging and drug development related to prostate cancer. -
PSMA Probe
PSMA-trillium is a PSMA-targeting compound that features a PSMA binder, a Macropa chelating molecule, and a pharmacokinetics modifier. This non-radioactive derivative of Actinium-225-PSMA-Trillium (BAY 3563254) offers enhanced PSMA targeting and optimized pharmacokinetic properties. PSMA-trillium effectively binds to Ac via the Macropa chelator and serves as a potent inhibitor of metastatic castration-resistant prostate cancer (mCRPC). It is a valuable tool for research into targeted therapies for prostate cancer. -
PSMA Tracer
BQ0413 is a potent PSMA tracer with a dissociation constant (KD) of 89 pM, demonstrating strong affinity for the prostate-specific membrane antigen. This compound exhibits efficient cellular uptake and a notable internalization rate of 44% in PC3-pip cells, making it suitable for research applications in tumor imaging. When radiolabeled with 99mTc, BQ0413 serves as an effective imaging agent for prostate cancer in preclinical studies. -
PSMA Ligand
PSMA-N5 is a potent PSMA ligand, exhibiting a Ki value of 0.71 nM. This compound serves as a PET radiotracer specifically for imaging prostate cancer, facilitating the visualization of tumors. PSMA-N5 is valuable for research applications in prostate cancer and other malignancies associated with prostate-specific membrane antigen. -
PSMA Inhibitor
PSMA-IN-2 is a potent inhibitor of Prostate-Specific Membrane Antigen (PSMA) with a Ki value of 1.07 nM. This compound exhibits promising in vivo near-infrared (NIR) imaging properties at an emission wavelength of 1088 nm and an excitation wavelength of 808 nm. PSMA-IN-2 is particularly applicable in NIRII image-guided tumor resection surgeries in models of PSMA-positive tumors, making it a valuable tool for cancer research and therapeutic interventions. -
PSMA Inhibitor
PSMA-IN-3 is a high-affinity inhibitor of Prostate-Specific Membrane Antigen (PSMA), demonstrating an IC50 value of 13 nM. This compound is particularly relevant for the development of 18F-labeled radioligands for positron emission tomography (PET) imaging to detect PSMA expression in prostate cancer. Researchers can utilize PSMA-IN-3 for studies aimed at advancing diagnostic imaging and therapeutic strategies in oncology. -
PSMA Inhibitor
DCFBC is a potent prostate-specific membrane antigen (PSMA) inhibitor, primarily utilized for small animal positron emission tomography (PET) imaging applications. Labeled with fluorine-18, [18F]DCFBC demonstrates preferential uptake in PSMA-expressing tumors, particularly in PIP tumors, while showing minimal uptake in FLU tumors. Additionally, while high accumulation in the kidneys and bladder is observed, the washout of radioactivity is faster compared to PIP tumors. This specificity positions [18F]DCFBC as a valuable tool for studying prostate cancer and assessing PSMA-targeted therapies. -
PSMA Inhibitor
(R)-Zadavotide guraxetan is a potent inhibitor of prostate-specific membrane antigen (PSMA), exhibiting significant antitumor activity. It is primarily utilized in research focused on prostate cancer, contributing to the understanding of targeted therapeutic approaches. This compound serves as a valuable tool for investigating the role of PSMA in cancer biology and evaluating efficacy in preclinical studies. -
PSMA Ligand
PSMA-MAL-5 is a prostate-specific membrane antigen (PSMA) ligand that covalently binds to Cys466 of the PSMA protein. This compound demonstrates significant biological activity, including high radiostability and tumor uptake when labeled with 177Lu and 225Ac. PSMA-MAL-5 is also effective in inhibiting tumor growth, making it suitable for applications in SPECT/CT imaging and radionuclide therapy for prostate cancer. -
Precursor of PSMA Ligands
PSMA precursor-1 is a key intermediate in the synthesis of prostate-specific membrane antigen (PSMA) ligands and fluorescent probes. It is utilized for the detection of PSMA in prostate cancer cell lines, specifically LNCaP and PC3. This compound plays a significant role in the development of targeted imaging agents and therapeutic strategies for prostate cancer research. -
SIK2/SIK3 Inhibitor
GLPG3970 is a selective inhibitor of SIK2 and SIK3, targeting these kinases to modulate their activity. This compound demonstrates significant potential in studying inflammatory responses and autoimmune diseases, contributing to the understanding of their underlying mechanisms and potential therapeutic approaches. Its role as a first-in-class inhibitor positions GLPG3970 as a valuable tool in biomedical research focused on these critical areas. -
SIK2/SIK3 Inhibitor
SK-124 is an orally active inhibitor of salt-inducible kinases 2 and 3 (SIK2/SIK3). It selectively inhibits SIK2 and SIK3, leading to enhanced levels of pro-peptide of type I collagen (P1NP) and C-terminal telopeptide of type I collagen (CTX). This modulation results in increased bone formation and bone mass, making SK-124 a valuable tool for research on bone metabolism and associated disorders. -
SIK Inhibitor
YKL-06-062 is a selectively potent inhibitor of salt-inducible kinases (SIKs), demonstrating IC50 values of 2.12 nM, 1.40 nM, and 2.86 nM for SIK1, SIK2, and SIK3, respectively. This compound is pivotal for research involving cellular stress responses, inflammatory processes, and metabolic regulation. Its specificity and efficacy make it a valuable tool for exploring SIK-related signaling pathways in various biological contexts. -
Sik3 Inhibitor
Pterosin B is an orally active indanone and a selective inhibitor of the SIK3 signaling pathway. It has demonstrated key biological activities, including the inhibition of Klf5 expression and a reduction in β-amyloid deposition, making it relevant in Alzheimer's disease research. Additionally, Pterosin B prevents chondrocyte hypertrophy and osteoarthritis in mouse models, while also inhibiting cardiomyocyte hypertrophy and improving cognitive impairment and glycemic control. This compound is valuable for studies related to arthritis, neurodegenerative disorders, pathological cardiac hypertrophy, and diabetes. -
SIK Inhibitor
WH-4-025 is an inhibitor of salt-inducible kinases (SIKs), which play a critical role in regulating various cellular processes, including metabolism, inflammation, and transcription. This compound has demonstrated significant biological activity by modulating SIK signaling pathways, making it a valuable tool for investigating the roles of SIKs in cellular response to environmental stressors. WH-4-025 is suitable for research applications aimed at understanding diseases linked to SIK dysregulation, such as metabolic disorders and cancer. -
SIK2 Inhibitor
SIC-19 is a selective inhibitor of SIK2, promoting its degradation through the ubiquitination pathway. This compound exhibits significant antiproliferative activity against cancer cells and enhances the sensitivity of these cells to PARP inhibitors, including Olaparib. Additionally, SIC-19 demonstrates efficacy in ovarian cancer organoids and xenograft models, making it a valuable tool for cancer research and therapeutic development. -
SIK Inhibitor
MR22 is a potent inhibitor of salt-inducible kinases (SIKs), demonstrating excellent selectivity in a representative kinase panel, while lacking activity against STE group kinases. This compound effectively induces centrosome dissociation and contributes to cell-cycle arrest in ovarian cancer cells. MR22 holds potential for research in cancer biology and the therapeutic targeting of SIK-related pathways. -
SIK Inhibitor
SIKs-IN-1 is a pyrimidine-5-carboxamide derivative that functions as an inhibitor of Salt-inducible kinases (SIKs). It modulates the balance between M1 and M2 macrophages, playing a crucial role in the inflammatory response. SIKs-IN-1 effectively inhibits SIK activity, leading to the upregulation of the anti-inflammatory cytokine IL-10 and the downregulation of the pro-inflammatory cytokine IL-12. This compound demonstrates significant anti-inflammatory effects in models of DSS-induced colitis, making it valuable for research into inflammatory diseases. -
SIK1/2 Inhibitor
SIK2-IN-3 is a selective inhibitor of SIK1 and SIK2, with IC50 values of 0.128 μM and 0.084 μM, respectively. This compound effectively inhibits the phosphorylation of CRTC3 and reduces pro-inflammatory cytokine production in myeloid cells. SIK2-IN-3 demonstrates potential in mitigating systemic and tissue inflammatory responses, as evidenced by its efficacy in a mouse anti-CD40 colitis model, making it a valuable tool for research in inflammation and immune response mechanisms. -
SIK2/3 Inhibitor
SIK2/3-IN-1 is a selective inhibitor of Salt-Inducible Kinases 2 and 3 (SIK2/3). It has demonstrated significant efficacy in inhibiting tumor growth in the MV4-11 acute myeloid leukemia (AML) mouse xenograft model, while maintaining animal body weight. This compound is valuable for investigating MEF2C-dependent pathways in acute myeloid leukemia research. -
CD36 Ligand
1-Palmitoyl-2-succinyl-sn-glycerophosphorylcholine is a glycerophosphorylcholine that targets scavenger receptor class B, specifically CD36. This compound accumulates at sites of oxidative stress in vivo and is implicated in the molecular mechanisms of tumor apoptosis. Its interaction with oxidized phospholipids (oxPLs) suggests potential applications in cancer research and studies related to oxidative stress and inflammation. -
CD36 Inhibitor
1-Palmitoyl-2-13(S)-HODE-sn-glycero-3-PC is a unique oxidized phospholipid that functions as a potent CD36 inhibitor. It features palmitic acid at the sn-1 position and 13(S)-HODE at the sn-2 position, allowing it to interfere with the binding of 125I-NO2-LDL to CD36-transfected 293 cells, exhibiting an IC50 value greater than 200 μM. This compound is useful for research applications exploring lipid interactions and receptor signaling pathways associated with CD36. -
STING Inhibitor
SN-011 is a selective inhibitor of the STING pathway, displaying an IC50 of 76 nM. By competing with cyclic dinucleotides (CDNs) for the binding site on the STING dimer, SN-011 effectively prevents CDN binding and subsequent STING activation. This compound is valuable for investigating STING-mediated autoimmune and inflammatory diseases, offering insights into therapeutic strategies targeting this critical signaling pathway. -
STING Inhibitor
STING-IN-2 is a potent covalent inhibitor of Stimulator of Interferon Genes (STING), effectively targeting both mouse and human STING isoforms. This compound is instrumental in studying the role of STING in autoinflammatory diseases, facilitating the exploration of therapeutic interventions. Its ability to modulate STING activity makes it a valuable tool for researchers investigating immune response and signaling pathways. -
Second Messenger/STING Agonist
Cyclic-di-GMP disodium functions as a STING agonist and serves as a crucial bacterial second messenger. It orchestrates various bacterial behaviors such as motility, virulence, biofilm formation, and cell cycle regulation. Additionally, cyclic-di-GMP disodium exhibits anti-cancer activity by inhibiting cell proliferation and promoting CD4 receptor expression along with inducing cell cycle arrest. This compound is valuable for applications in cancer research. -
STING Activator
cGAMP disodium, a potent STING activator, functions as an endogenous second messenger that triggers the production of interferons in response to cytosolic DNA. It initiates the stimulator of interferon genes (STING) pathway, resulting in an immune response marked by the production of type I interferons and various immune mediators. This compound is widely used in research focused on innate immunity, cancer immunotherapy, and understanding viral infections. -
STING Activator
STING agonist-12 (Compound 53) is a potent agonist that activates the human stimulator of interferon genes (STING) pathway, exhibiting an EC50 value of 185 nM. This compound serves as a valuable tool for immunological research, particularly in studying innate immune responses and antitumor immunity. Its ability to modulate STING activity makes it a promising candidate for assessing therapeutic strategies in cancer and infectious diseases. -
STING Molecular Glue
NVS-STG2 is a molecular glue that targets the STING receptor by binding to the interstitial regions of adjacent STING dimers, thereby enhancing STING signaling. This compound promotes the activity of cGAMP, leading to the formation of larger and more stable oligomers, which amplifies the immune response. NVS-STG2 has demonstrated significant antitumor effects in preclinical animal models, making it a valuable tool for cancer immunotherapy research. -
STING Agonist
STING agonist-20 is a potent agonist of the STING pathway, which plays a critical role in the innate immune response. This compound is utilized in the synthesis of XMT-2056, serving as an important tool in cancer research and the investigation of inflammatory and immune-related diseases. Its application as a vaccine adjuvant allows for enhanced immune activation, making it a valuable reagent in immunotherapy studies. -
STING Agonist
STING Agonist-22 (CF501) is a potent non-nucleotide agonist targeting the stimulator of interferon genes (STING). This compound effectively activates STING to induce a type I interferon (IFN-I) response and drive the production of proinflammatory cytokines. STING Agonist-22 serves as an adjuvant to enhance protein vaccine efficacy, promoting robust and sustained immune protection. It is particularly relevant for research on SARS-CoV-2 variants and related sarbecovirus diseases. -
STING Antagonist
STING antagonist-1 is a selective antagonist of the Stimulator of Interferon Genes (STING) pathway, exhibiting an IC50 of 3.8 nM. This compound is valuable for research applications related to autoimmune and inflammatory diseases, allowing for the investigation of STING-mediated cellular responses and therapeutic interventions. -
Second Messenger/STING Agonist
Cyclic-di-GMP diammonium is a second messenger with significant activity as a STING agonist. It plays a crucial role in regulating bacterial growth, motility, virulence, biofilm formation, and cell cycle progression. In addition to its bacterial applications, cyclic-di-GMP diammonium demonstrates anti-cancer properties, promoting cell cycle arrest and increasing CD4 receptor expression. This reagent is valuable for investigations in cancer research. -
STING Inhibitor
LB244 is a STING inhibitor that functions by modulating the STING signaling pathway to reduce inflammation. It exhibits a potent inhibitory effect (EC50 = 0.8 μM) on STING-dependent inflammatory responses. While LB244 shows promising potential in preclinical studies, its pharmacokinetic profile suggests limited oral bioavailability in murine models. This compound is suitable for research applications focused on understanding STING-related inflammatory disorders. -
STING Agonist
E7766 diammonium salt is a macrocycle-bridged STING agonist that exhibits a dissociation constant (Kd) of 40 nM. This compound demonstrates potent pan-genotypic activity and significant antitumor effects, making it a valuable tool for cancer immunotherapy research. It is suitable for studies focused on modulating the STING pathway to enhance immune responses against tumors. -
STING Agonist
IACS-8803 disodium is a potent cyclic dinucleotide and a selective STING agonist. It activates the STING pathway, leading to enhanced immune responses against tumors. This compound is utilized in research related to cancer immunotherapy and the modulation of immune signaling pathways. -
STING Agonist
Dazostinag disodium is a potent STING agonist that activates the STING signaling pathway, leading to the production of type I interferons. This compound enhances immune responses, resulting in complete tumor regressions and the establishment of long-lasting memory T-cell immunity. Dazostinag disodium is valuable for research applications focused on cancer immunotherapy and the modulation of the immune system. -
STING Agonist
diABZI-C2-NH2 is a potent STING (Stimulator of Interferon Genes) agonist that features a primary amine group. This compound activates the STING pathway, leading to enhanced type I interferon production and immune response modulation. diABZI-C2-NH2 is valuable for research applications focused on immunotherapy, autoimmunity, and infectious disease, making it a key tool in studying the role of STING in immune signaling. -
STING Inhibitor
STING-IN-3 is a potent inhibitor of the stimulator of interferon genes (STING), specifically targeting both human and murine STING. It covalently modifies the conserved transmembrane cysteine residue at position 91, effectively preventing activation-induced palmitoylation. This activity provides valuable utility in research applications exploring STING-related pathways in immune response and therapeutic interventions in autoimmune diseases and cancer. -
STING Inhibitor
SN-001 is a selective inhibitor of the STING (Stimulator of Interferon Genes) pathway, exhibiting an IC50 of 3.82 μM. This compound is valuable for investigating the role of STING in immune responses and inflammatory diseases. Its inhibitory activity allows for the evaluation of STING's effects on cytokine production and other immune-related pathways, making it a useful tool for research in immunology and drug development. -
STING Inhibitor
STING-IN-4 is a potent STING inhibitor that effectively reduces the expression and activation of STING and nuclear factor-κB (NF-κB) signaling pathways. This compound exhibits significant anti-inflammatory activity, making it a valuable tool for investigating sepsis and related inflammatory conditions. Researchers can utilize STING-IN-4 to explore the therapeutic potential of modulating STING activity in various biological contexts. -
STING Agonist
STING agonist-23 is a small-molecule STING agonist that functions non-nucleotidally to activate the STING pathway. This enhancement leads to increased phosphorylation of STING, TBK1, and IRF3, resulting in elevated production of key cytokines such as IFN-β, IL-6, CXCL-10, TNF-α, ISG-15, and CCL-5 in tumor cells. STING agonist-23 is also shown to exhibit antiviral activity against SARS-CoV strains, making it a valuable tool for immunotherapy and virology research. -
STING Agonist
MSA-2 dimer is a selective, orally active non-nucleotide STING agonist that demonstrates a binding affinity (Kd) of 145 μM. This compound promotes long-term antitumor effects and enhances immunogenic activity by non-covalently interacting with STING in a dimeric form, offering superior permeability compared to cyclic dinucleotides. MSA-2 dimer is particularly valuable for research into cancer immunotherapy and the modulation of innate immune responses. -
STING Agonist
SR-717 free acid is a non-nucleotide STING agonist that demonstrates effective activation in immune responses, exhibiting EC50 values of 2.1 μM and 2.2 μM in ISG-THP1 wild-type and cGAS knockout cell lines, respectively. This compound serves as a stable cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) mimetic, enhancing antitumor activity through stimulation of the STING pathway. Its potential applications in cancer immunotherapy and the study of innate immunity make it a valuable tool for researchers in the field of immunology. -
STING Antagonist
STING antagonist-2 is a potent inhibitor of the Stimulator of Interferon Genes (STING), exhibiting a pIC50 of 8.9. This compound is primarily utilized in immunity research to investigate the modulation of STING-mediated immune responses. Its application extends to studies focused on immune evasion and potential therapeutic approaches in autoimmune disorders. -
STING Inhibitor
STING-IN-7 is a potent inhibitor of the Stimulator of Interferon Genes (STING) pathway, demonstrating an IC50 of 11.5 nM. This compound effectively inhibits the phosphorylation of STING, interferon regulatory factor 3 (IRF3), and TANK-binding kinase 1 (TBK1). STING-IN-7 is valuable for investigating the role of STING modulation in autoimmune and inflammatory disease research. -
STING Modulator
SB24011 is a selective STING modulator that inhibits the TRIM29-STING protein-protein interaction. By binding to STING, it effectively prevents TRIM29-induced K48-linked ubiquitination, leading to an increase in intracellular STING protein levels. This compound promotes the expression of inflammatory cytokines and enhances STING-mediated immune responses, demonstrating abscopal antitumor activity that stimulates tumor regression and T cell infiltration. SB24011 is particularly relevant for research on colon cancer and melanoma, showing potential synergy when used in conjunction with STING agonists or anti-PD1 antibodies. -
STING Agonist
diABZI STING Agonist-1 (tautomerism) is a selective agonist of the STING (Stimulator of Interferon Genes) receptor, enhancing innate immune responses. It exhibits potent biological activity, with EC50 values of 130 nM in human and 186 nM in mouse systems. This compound is valuable for research applications focused on immunotherapy, cancer treatment, and studies involving the modulation of immune pathways. -
STING Agonist
STING agonist-17 is a potent STING agonist that activates the STING pathway with an IC50 value of 0.062 nM. This compound exhibits significant anti-cancer activity, promoting immune response and tumor immunization. It is valuable for research applications targeting cancer therapy and immune modulation. -
STING Agonist
STING agonist-16 is a specific stimulator of interferon genes (STING) that activates the intrinsic immune response. This compound exhibits significant antiviral and antitumor activities by promoting the production of type I interferons and enhancing immune cell activation. STING agonist-16 is valuable for research applications focused on cancer immunotherapy and viral infections.
